CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Dulaglutide

Dulaglutide

Last Updated: November 17, 2015

Result type: Reports

Project Number: SR0462-000

Product Line: Reimbursement Review

Generic Name: Dulaglutide

Brand Name: Trulicity

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Diabetes mellitus, Type 2

Indications: Diabetes mellitus, Type 2

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 16, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions

Dulaglutide

Files